RxSight Inc

RXST

Equity

ISIN null / Valor 112649019

NASDAQ (2025-11-19)

USD 9.50-1.04%

RxSight Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

RxSight Inc., based in Aliso Viejo, California, is a medical technology company specializing in ophthalmic solutions. The company has developed and commercialized the Light Adjustable Lens™ (LAL®/LAL+™), a unique intraocular lens that can be customized post-cataract surgery to optimize visual outcomes for patients. This innovation allows for precise adjustments to the lens after implantation, enhancing the cataract surgery experience. RxSight aims to transform the field of premium cataract surgery by enabling surgeons to tailor treatments to the specific needs of each patient's eye. The company leverages extensive industry experience and expertise in ophthalmology to advance its mission.

Summarized from source with an LLMView SourceSector: Technology

Second Quarter 2025 Revenue

Preliminary revenue for RxSight Inc. in Q2 2025 is expected to be approximately $33.6 million, marking a 4% decrease year-over-year and an 11% decline compared to Q1 2025. This decrease is primarily driven by reduced sales of Light Delivery Devices (LDD™) and a slight decrease in Light Adjustable Lenses (LAL®/LAL+®) procedures month-over-month.

Product Sales Performance

Sales of 27,380 Light Adjustable Lenses represent a 1% decrease in procedure volume from Q1 2025 but a 13% increase compared to Q2 2024. Conversely, sales of 40 Light Delivery Devices indicate a significant decline of 45% from Q1 2025 and 49% from Q2 2024, impacting overall revenue figures.

Installed Base Growth

As of June 30, 2025, RxSight Inc.'s installed base expanded to 1,084 Light Delivery Devices, a 34% increase from 810 devices at the end of Q2 2024. This growth reflects the company’s ongoing efforts to enhance its market presence and support its clinical partners.

Revised 2025 Guidance

RxSight Inc. has updated its full-year 2025 guidance, projecting revenue between $120.0 million and $130.0 million, down from the previously forecasted $160.0 million to $175.0 million. The company expects gross margins to improve to 72%-74% from 71%-73%, while operating expenses are projected to rise to $145.0-$155.0 million, including non-cash stock-based compensation.

Cash Position

The company reported preliminary cash, cash equivalents, and short-term investments of $227.5 million as of June 30, 2025, showing a slight decrease of approximately $1.8 million from the $229.3 million reported at the end of Q1 2025.

Summarized from source with an LLMView Source

Key figures

-78.9%1Y

-28.1%3Y

%5Y

Performance

89.1%1Y

67.7%3Y

72.2%5Y

Volatility